Amin Rostami-Hodjegan

List of Publications by Year
in descending order

316	18,313	10373	19169
papers	citations	72 h-index	118 g-index

324	324	324	10398
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Proteomics of colorectal cancer liver metastasis: A quantitative focus on drug elimination and pharmacodynamics effects. British Journal of Clinical Pharmacology, 2022, 88, 1811-1823.	1.1	13
2	In Vitro to In Vivo Extrapolation Linked to Physiologically Based Pharmacokinetic Models for Assessing the Brain Drug Disposition. AAPS Journal, 2022, 24, 28.	2.2	8
3	Proof of Concept in Assignment of Within-Subject Variability During Virtual Bioequivalence Studies: Propagation of Intra-Subject Variation in Gastrointestinal Physiology Using Physiologically Based Pharmacokinetic Modeling. AAPS Journal, 2022, 24, 21.	2.2	12
4	A family of QconCATs (Quantification conCATemers) for the quantification of human pharmacological target proteins. Journal of Proteomics, 2022, 261, 104572.	1.2	4
5	Liquid Biopsy for Patient Characterization in Cardiovascular Disease: Verification against Markers of Cytochrome P450 and Pâ€Glycoprotein Activities. Clinical Pharmacology and Therapeutics, 2022, 111, 1268-1277.	2.3	22
6	Label-Free but Still Constrained: Assessment of Global Proteomic Strategies for the Quantification of Hepatic Enzymes and Transporters . Drug Metabolism and Disposition, 2022, , DMD-AR-2021-000780.	1.7	2
7	Quality Assurance of PBPK Modeling Platforms and Guidance on Building, Evaluating, Verifying and Applying PBPK Models Prudently under the Umbrella of Qualification: Why, When, What, How and By Whom?. Pharmaceutical Research, 2022, 39, 1733-1748.	1.7	19
8	Proteomic quantification of perturbation to pharmacokinetic target proteins in liver disease. Journal of Proteomics, 2022, 263, 104601.	1.2	5
9	Quantitative Proteomics of Hepatic Drugâ€Metabolizing Enzymes and Transporters in Patients With Colorectal Cancer Metastasis. Clinical Pharmacology and Therapeutics, 2022, 112, 699-710.	2.3	7
10	Effect of Chronic Kidney Disease on the Renal Secretion via Organic Anion Transporters 1/3: Implications for Physiologicallyâ€Based Pharmacokinetic Modeling and Dose Adjustment. Clinical Pharmacology and Therapeutics, 2022, 112, 643-652.	2.3	12
11	Label-Free Quantitative Proteomics and Substrate-Based Mass Spectrometry Imaging of Xenobiotic Metabolizing Enzymes in Ex Vivo Human Skin and a Human Living Skin Equivalent Model. Drug Metabolism and Disposition, 2021, 49, 39-52.	1.7	12
12	Model-Informed Precision Dosing: Background, Requirements, Validation, Implementation, and Forward Trajectory of Individualizing Drug Therapy. Annual Review of Pharmacology and Toxicology, 2021, 61, 225-245.	4.2	74
13	Physiologicalâ€based pharmacokinetic modeling trends in pharmaceutical drug development over the last 20â€years; inâ€depth analysis of applications, organizations, and platforms. Biopharmaceutics and Drug Disposition, 2021, 42, 107-117.	1.1	69
14	Quantification of Proteins Involved in Intestinal Epithelial Handling of Xenobiotics. Clinical Pharmacology and Therapeutics, 2021, 109, 1136-1146.	2.3	22
15	Liquid Biopsy Enables Quantification of the Abundance and Interindividual Variability of Hepatic Enzymes and Transporters. Clinical Pharmacology and Therapeutics, 2021, 109, 222-232.	2.3	54
16	Does â€œBirthâ€•as an Event Impact Maturation Trajectory of Renal Clearance via Glomerular Filtration? Reexamining Data in Preterm and Fullâ€Term Neonates by Avoiding the Creatinine Bias. Journal of Clinical Pharmacology, 2021, 61, 159-171.	1.0	25
17	Scientific considerations to move towards biowaiver for biopharmaceutical classification system class III drugs: How modeling and simulation can help. Biopharmaceutics and Drug Disposition, 2021, 42, 118-127.	1.1	11
18	Clinical Investigation on Endogenous Biomarkers to Predict Strong OAT-Mediated Drugâ€“Drug Interactions. Clinical Pharmacokinetics, 2021, 60, 1187-1199.	1.6	20

#	Article	IF	Citations
19	Proteomic Quantification of Changes in Abundance of Drug-Metabolizing Enzymes and Drug Transporters in Human Liver Cirrhosis: Different Methods, Similar Outcomes. Drug Metabolism and Disposition, 2021, 49, 610-618.	1.7	15
20	Opening a debate on openâ€source modeling tools: Pouring fuel on fire versus extinguishing the flare of a healthy debate. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 420-427.	1.3	13
21	Hepatic Scaling Factors for In Vitroâ€“In Vivo Extrapolation of Metabolic Drug Clearance in Patients with Colorectal Cancer with Liver Metastasis. Drug Metabolism and Disposition, 2021, 49, 563-571.	1.7	9
22	Population pharmacokinetic modeling and simulation to support qualification of pyridoxic acid as endogenous biomarker of OAT1/3 renal transporters. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 467-477.	1.3	9
23	Bringing Microphysiological Systems to Practical Use: Evaluation of transporterâ€mediated DDI and Renal Clearance. FASEB Journal, 2021, 35, .	0.2	0
24	Application of proteomic data in the translation of in vitro observations to associated clinical outcomes. Drug Discovery Today: Technologies, 2021, 39, 13-22.	4.0	5
25	Review article: time to revisit Childâ€Pugh score as the basis for predicting drug clearance in hepatic impairment. Alimentary Pharmacology and Therapeutics, 2021, 54, 388-401.	1.9	25
26	Non-uniformity of Changes in Drug-Metabolizing Enzymes and Transporters in Liver Cirrhosis: Implications for Drug Dosage Adjustment. Molecular Pharmaceutics, 2021, 18, 3563-3577.	2.3	33
27	Quantitative Proteomic Map of Enzymes and Transporters in the Human Kidney: Stepping Closer to Mechanistic Kidney Models to Define Local Kinetics. Clinical Pharmacology and Therapeutics, 2021, 110, 1389-1400.	2.3	14
28	Editorial: Precision Medicine: Impact of Cytochromes P450 and Transporters Genetic Polymorphisms, Drug-Drug Interactions, Disease on Safety and Efficacy of Drugs. Frontiers in Pharmacology, 2021, 12, 834717.	1.6	1
29	Characterization of CYP2B6 K262R allelic variants by quantitative allele-specific proteomics using a QconCAT standard. Journal of Pharmaceutical and Biomedical Analysis, 2020, 178, 112901.	1.4	7
30	IMI â€“ Oral biopharmaceutics tools project â€“ Evaluation of bottom-up PBPK prediction success part 4: Prediction accuracy and software comparisons with improved data and modelling strategies. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 156, 50-63.	2.0	27
31	Public Workshop Summary Report on Fiscal Year 2021 Generic Drug Regulatory Science Initiatives: Data Analysis and Modelâ€Based Bioequivalence. Clinical Pharmacology and Therapeutics, 2020, 110, 1190-1195.	2.3	7
32	Physiologically Based Pharmacokinetics as a Component of Modelâ€Informed Drug Development: Where We Were, Where We Are, and Where We Are Heading. Journal of Clinical Pharmacology, 2020, 60, S12-S16.	1.0	6
33	Considerations and Caveats when Applying Global Sensitivity Analysis Methods to Physiologically Based Pharmacokinetic Models. AAPS Journal, 2020, 22, 93.	2.2	30
34	Mass spectrometryâ€based abundance atlas of ABC transporters in human liver, gut, kidney, brain and skin. FEBS Letters, 2020, 594, 4134-4150.	1.3	21
35	Application of the Nested Enzymeâ€Withinâ€Enterocyte (NEWE) Turnover Model for Predicting the Time Course of Pharmacodynamic Effects. CPT: Pharmacometrics and Systems Pharmacology, 2020, 9, 617-627.	1.3	1
36	Proteomic characterisation of drug metabolising enzymes and drug transporters in pig liver. Xenobiotica, 2020, 50, 1208-1219.	0.5	4

#	Article	IF	Citations
37	Translational Modeling Strategies for Orally Administered Drug Products: Academic, Industrial and Regulatory Perspectives. Pharmaceutical Research, 2020, 37, 95.	1.7	8
38	Mechanistic Models as Framework for Understanding Biomarker Disposition: Prediction of Creatinineâ€Drug Interactions. CPT: Pharmacometrics and Systems Pharmacology, 2020, 9, 282-293.	1.3	20
39	The Influence of Drug Properties and Ontogeny of Transporters on Pediatric Renal Clearance through Glomerular Filtration and Active Secretion: a Simulation-Based Study. AAPS Journal, 2020, 22, 87.	2.2	18
40	A Novel PhysiologicallyÂBased Model of Creatinine Renal Disposition to Integrate Current Knowledge of Systems Parameters and Clinical Observations. CPT: Pharmacometrics and Systems Pharmacology, 2020, 9, 310-321.	1.3	14
41	Mass Spectrometry of Human Transporters. Annual Review of Analytical Chemistry, 2020, 13, 223-247.	2.8	7
42	Virtual Twins: Understanding the Data Required for Modelâ€Informed Precision Dosing. Clinical Pharmacology and Therapeutics, 2020, 107, 742-745.	2.3	38
43	Quantitative Proteomics of Clinically Relevant Drug-Metabolizing Enzymes and Drug Transporters and Their Intercorrelations in the Human Small Intestine. Drug Metabolism and Disposition, 2020, 48, 245-254.	1.7	73
44	Six years of progress in the oral biopharmaceutics area â€“ A summary from the IMI OrBiTo project. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 152, 236-247.	2.0	21
45	Scaling Factors for Clearance in Adult Liver Cirrhosis. Drug Metabolism and Disposition, 2020, 48, 1271-1282.	1.7	16
46	Response to â€œDetermining Allele-Specific Protein Expression (ASPE) Using a Novel Quantitative Concatamer Based Proteomics Methodâ€• Journal of Proteome Research, 2019, 18, 574.	1.8	2
47	Quantitative mass spectrometry-based proteomics in the era of model-informed drug development: Applications in translational pharmacology and recommendations for best practice. , 2019, 203, 107397.		20
48	A Pediatric Covariate Function for CYP3A-Mediated Midazolam Clearance Can Scale Clearance of Selected CYP3A Substrates in Children. AAPS Journal, 2019, 21, 81.	2.2	8
49	Quantitative Translation of Microfluidic Transporter in Vitro Data to in Vivo Reveals Impaired Albumin-Facilitated Indoxyl Sulfate Secretion in Chronic Kidney Disease. Molecular Pharmaceutics, 2019, 16, 4551-4562.	2.3	30
50	Assessing Potential Drugâ€“Drug Interactions Between Dabigatran Etexilate and a Pâ€Glycoprotein Inhibitor in Renal Impairment Populations Using Physiologically Based Pharmacokinetic Modeling. CPT: Pharmacometrics and Systems Pharmacology, 2019, 8, 118-126.	1.3	17
51	Toward a Consensus on Applying Quantitative Liquid Chromatographyâ€Tandem Mass Spectrometry Proteomics in Translational Pharmacology Research: A White Paper. Clinical Pharmacology and Therapeutics, 2019, 106, 525-543.	2.3	77
52	Come Dance With Me: Transformative Changes in theÂScience and Practice of Drugâ€“Drug Interactions. Clinical Pharmacology and Therapeutics, 2019, 105, 1272-1278.	2.3	8
53	Accounting for inter-correlation between enzyme abundance: a simulation study to assess implications on global sensitivity analysis within physiologically-based pharmacokinetics. Journal of Pharmacokinetics and Pharmacodynamics, 2019, 46, 137-154.	0.8	16
54	Scaling Drug Clearance from Adults to the Young Children for Drugs Undergoing Hepatic Metabolism: A Simulation Study to Search for the Simplest Scaling Method. AAPS Journal, 2019, 21, 38.	2.2	11

#	Article	IF	Citations
55	Drugâ€“Drug Interactions: Progress Over the Past Decade and Looking Ahead to the Future. Clinical Pharmacology and Therapeutics, 2019, 105, 1289-1291.	2.3	2
56	Proteomic Quantification of Human Bloodâ€“Brain Barrier SLC and ABC Transporters in Healthy Individuals and Dementia Patients. Molecular Pharmaceutics, 2019, 16, 1220-1233.	2.3	85
57	The nested enzyme-within-enterocyte (NEWE) turnover model for predicting dynamic drug and disease effects on the gut wall. European Journal of Pharmaceutical Sciences, 2019, 131, 195-207.	1.9	5
58	Towards Further Verification of Physiologically-Based Kidney Models: Predictability of the Effects of Urine-Flow and Urine-pH on Renal Clearance. Journal of Pharmacology and Experimental Therapeutics, 2019, 368, 157-168.	1.3	17
59	Quantification of Proteins Involved in Drug Metabolism and Disposition in the Human Liver Using Label-Free Global Proteomics. Molecular Pharmaceutics, 2019, 16, 632-647.	2.3	65
60	What Does it Take to Make Model-Informed Precision Dosing Common Practice? Report from the 1st Asian Symposium on Precision Dosing. AAPS Journal, 2019, 21, 17.	2.2	29
61	Toward Dynamic Prescribing Information: Codevelopment of Companion Modelâ€Informed Precision Dosing Tools in Drug Development. Clinical Pharmacology in Drug Development, 2019, 8, 418-425.	0.8	26
62	Precision dosing to avoid adverse drug reactions. Therapeutic Advances in Drug Safety, 2019, 10, 204209861989414.	1.0	17
63	Precision medicine technology hype or reality? The example of computer-guided dosing. F1000Research, 2019, 8, 1709.	0.8	4
64	Core Entrustable Professional Activities in Clinical Pharmacology: Pearls for Clinical Practice. Journal of Clinical Pharmacology, 2018, 58, 704-716.	1.0	10
65	Drugs Being Eliminated via the Same Pathway Will Not Always Require Similar Pediatric Dose Adjustments. CPT: Pharmacometrics and Systems Pharmacology, 2018, 7, 175-185.	1.3	19
66	Identification and quantification of bloodâ€“brain barrier transporters in isolated rat brain microvessels. Journal of Neurochemistry, 2018, 146, 670-685.	2.1	59
67	Physiologically Based Pharmacokinetic Modeling to Identify Physiological and Molecular Characteristics Driving Variability in Drug Exposure. Clinical Pharmacology and Therapeutics, 2018, 104, 1219-1228.	2.3	29
68	Implications of intercorrelation between hepatic CYP3A4â€CYP2C8 enzymes for the evaluation of drugâ€“drug interactions: a case study with repaglinide. British Journal of Clinical Pharmacology, 2018, 84, 972-986.	1.1	19
69	Fetal Physiologically-Based Pharmacokinetic Models: Systems Information on Fetal Biometry and Gross Composition. Clinical Pharmacokinetics, 2018, 57, 1149-1171.	1.6	27
70	Revisiting Principles Behind Drug Clearance and Organ Extraction. Clinical Pharmacology and Therapeutics, 2018, 103, 388-389.	2.3	2
71	Data Generated by Quantitative Liquid Chromatography-Mass Spectrometry Proteomics Are Only the Start and Not the Endpoint: Optimization of Quantitative Concatemer-Based Measurement of Hepatic Uridine-5â€²-Diphosphateâ€“Glucuronosyltransferase Enzymes with Reference to Catalytic Activity. Drug Metabolism and Disposition, 2018, 46, 805-812.	1.7	19
72	Reverse Translation in PBPK and QSP: Going Backwards in Order to Go Forward With Confidence. Clinical Pharmacology and Therapeutics, 2018, 103, 224-232.	2.3	71

#	Article	IF	Citations
73	Prediction of olanzapine exposure in individual patients using physiologically based pharmacokinetic modelling and simulation. British Journal of Clinical Pharmacology, 2018, 84, 462-476.	1.1	53
74	Dose adjustment in orphan disease populations: the quest to fulfill the requirements of physiologically based pharmacokinetics. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 1315-1330.	1.5	11
75	GASP and FASP are Complementary for LCâ€"MS/MS Proteomic Analysis of Drugâ€Metabolizing Enzymes and Transporters in Pig Liver. Proteomics, 2018, 18, e1800200.	1.3	12
76	Can Population Modelling Principles be Used to Identify Key PBPK Parameters for Paediatric Clearance Predictions? An Innovative Application of Optimal Design Theory. Pharmaceutical Research, 2018, 35, 209.	1.7	8
77	Physiologically based pharmacokinetic modelling to guide drug delivery in older people. Advanced Drug Delivery Reviews, 2018, 135, 85-96.	6.6	46
78	Firstâ€Pass CYP3Aâ€Mediated Metabolism of Midazolam in the Gut Wall and Liver in Preterm Neonates. CPT: Pharmacometrics and Systems Pharmacology, 2018, 7, 374-383.	1.3	23
79	Application of Physiologically Based Pharmacokinetic (PBPK) Modeling Within a Bayesian Framework to Identify Poor Metabolizers of Efavirenz (PM), Using a Test Dose of Efavirenz. Frontiers in Pharmacology, 2018, 9, 247.	1.6	4
80	Past, Present, and Future of Bioequivalence: Improving Assessment and Extrapolation of Therapeutic Equivalence for Oral Drug Products. Journal of Pharmaceutical Sciences, 2018, 107, 2519-2530.	1.6	15
81	Precision dosing in clinical medicine: present and future. Expert Review of Clinical Pharmacology, 2018, 11, 743-746.	1.3	60
82	Comment on â€œEffect of Age-Related Factors on the Pharmacokinetics of Lamotrigine and Potential Implications for Maintenance Dose Optimisation in Future Clinical Trialsâ€• Clinical Pharmacokinetics, 2018, 57, 1471-1472.	1.6	2
83	Characterization of Intestinal and Hepatic CYP3A-Mediated Metabolism of Midazolam in Children Using a Physiological Population Pharmacokinetic Modelling Approach. Pharmaceutical Research, 2018, 35, 182.	1.7	24
84	Comment on â€œIn Silico Modeling of Gastrointestinal Drug Absorption: Predictive Performance of Three Physiologically-Based Absorption Modelsâ€• Molecular Pharmaceutics, 2017, 14, 336-339.	2.3	8
85	Quantifying gut wall metabolism: methodology matters. Biopharmaceutics and Drug Disposition, 2017, 38, 155-160.	1.1	21
86	Optimization of intestinal microsomal preparation in the rat: A systematic approach to assess the influence of various methodologies on metabolic activity and scaling factors. Biopharmaceutics and Drug Disposition, 2017, 38, 187-208.	1.1	17
87	Application of the MechPeff model to predict passive effective intestinal permeability in the different regions of the rodent small intestine and colon. Biopharmaceutics and Drug Disposition, 2017, 38, 94-114.	1.1	42
88	Microsomal and Cytosolic Scaling Factors in Dog and Human Kidney Cortex and Application for In Vitro-In Vivo Extrapolation of Renal Metabolic Clearance. Drug Metabolism and Disposition, 2017, 45, 556-568.	1.7	29
89	Why Has Modelâ€Informed Precision Dosing Not Yet Become Common Clinical Reality? Lessons From the Past and a Roadmap for the Future. Clinical Pharmacology and Therapeutics, 2017, 101, 646-656.	2.3	169
90	Global Proteomic Analysis of Human Liver Microsomes: Rapid Characterization and Quantification of Hepatic Drug-Metabolizing Enzymes. Drug Metabolism and Disposition, 2017, 45, 666-675.	1.7	42

#	Article	IF	Citations
91	Professor Yuichi Sugiyama: A Brilliant, Creative, Amicable, Charming, and Humorous Pharmaceutical Scientist. Journal of Pharmaceutical Sciences, 2017, 106, 2188-2194.	1.6	0
92	The Constraints, Construction, and Verification of a Strain-Specific Physiologically Based Pharmacokinetic Rat Model. Journal of Pharmaceutical Sciences, 2017, 106, 2826-2838.	1.6	18
93	Systems Toxicology: Real World Applications and Opportunities. Chemical Research in Toxicology, 2017, 30, 870-882.	1.7	93
94	Revisiting the role of gut wall in the fate of orally administered drugs: Why now and to what effect?. Biopharmaceutics and Drug Disposition, 2017, 38, 87-93.	1.1	3
95	The absorption kinetics of ketoconazole plays a major role in explaining the reported variability in the level of interaction with midazolam: Interplay between formulation and inhibition of gut wall and liver metabolism. Biopharmaceutics and Drug Disposition, 2017, 38, 260-270.	1.1	14
96	Variability in Mass Spectrometry-based Quantification of Clinically Relevant Drug Transporters and Drug Metabolizing Enzymes. Molecular Pharmaceutics, 2017, 14, 3142-3151.	2.3	102
97	Virtual bioequivalence for achlorhydric subjects: The use of PBPK modelling to assess the formulation-dependent effect of achlorhydria. European Journal of Pharmaceutical Sciences, 2017, 109, 111-120.	1.9	47
98	Utility of Model-Based Approaches for Informing Dosing Recommendations in Specific Populations: Report From the Public AAPS Workshop. Journal of Clinical Pharmacology, 2017, 57, 105-109.	1.0	12
99	Quantitative Characterization of Major Hepatic UDP-Glucuronosyltransferase Enzymes in Human Liver Microsomes: Comparison of Two Proteomic Methods and Correlation with Catalytic Activity. Drug Metabolism and Disposition, 2017, 45, 1102-1112.	1.7	40
100	IMI â€“ Oral biopharmaceutics tools project â€“ Evaluation of bottom-up PBPK prediction success part 2: An introduction to the simulation exercise and overview of results. European Journal of Pharmaceutical Sciences, 2017, 96, 610-625.	1.9	58
101	Allometric Scaling of Clearance in Paediatric Patients: When Does the Magic of 0.75 Fade?. Clinical Pharmacokinetics, 2017, 56, 273-285.	1.6	86
102	IMI â€“ oral biopharmaceutics tools project â€“ evaluation of bottom-up PBPK prediction success part 1: Characterisation of the OrBiTo database of compounds. European Journal of Pharmaceutical Sciences, 2017, 96, 598-609.	1.9	34
103	IMI â€“ Oral biopharmaceutics tools project â€“ Evaluation of bottom-up PBPK prediction success part 3: Identifying gaps in system parameters by analysing In Silico performance across different compound classes. European Journal of Pharmaceutical Sciences, 2017, 96, 626-642.	1.9	41
104	Biopharmaceutics data management system for anonymised data sharing and curation: First application with orbito IMI project. Computer Methods and Programs in Biomedicine, 2017, 140, 29-44.	2.6	6
105	Meet Our Co-Editor. Current Drug Metabolism, 2017, 18, 265-265.	0.7	0
106	Delineating the Role of Various Factors in Renal Disposition of Digoxin through Application of Physiologically Based Kidney Model to Renal Impairment Populations. Journal of Pharmacology and Experimental Therapeutics, 2017, 360, 484-495.	1.3	56
107	Role of pharmacokinetic modeling and simulation in precision dosing of anticancer drugs. Translational Cancer Research, 2017, 6, S1512-S1529.	0.4	26
108	Ontogeny of Hepatic Drug Transporters and Relevance to Drugs Used in Pediatrics. Drug Metabolism and Disposition, 2016, 44, 992-998.	1.7	32

#	Article	IF	Citations
109	Key to Opening Kidney for In Vitroâ€“In Vivo Extrapolation Entrance in Health and Disease: Part I: In Vitro Systems and Physiological Data. AAPS Journal, 2016, 18, 1067-1081.	2.2	38
110	Novel minimal physiologically-based model for the prediction of passive tubular reabsorption and renal excretion clearance. European Journal of Pharmaceutical Sciences, 2016, 94, 59-71.	1.9	44
111	Breast Cancer Resistance Protein Abundance, but Not mRNA Expression, Correlates With Estrone-3-Sulfate Transport in Caco-2. Journal of Pharmaceutical Sciences, 2016, 105, 1370-1375.	1.6	5
112	Prediction of Drug-Drug Interactions Arising from CYP3A induction Using a Physiologically Based Dynamic Model. Drug Metabolism and Disposition, 2016, 44, 821-832.	1.7	80
113	Development of a Novel Simplified PBPK Absorption Model to Explain the Higher Relative Bioavailability of the OROSÂ® Formulation of Oxybutynin. AAPS Journal, 2016, 18, 1532-1549.	2.2	23
114	Application of a physiologically based pharmacokinetic model for the evaluation of single-point plasma phenotyping method of CYP2D6. European Journal of Pharmaceutical Sciences, 2016, 92, 131-136.	1.9	5
115	Key to Opening Kidney for In Vitro-In Vivo Extrapolation Entrance in Health and Disease: Part II: Mechanistic Models and In Vitro-In Vivo Extrapolation. AAPS Journal, 2016, 18, 1082-1094.	2.2	29
116	Semiphysiologically based pharmacokinetic model for midazolam and CYP3A mediated metabolite 1â€ŒOHâ€midazolam in morbidly obese and weight loss surgery patients. CPT: Pharmacometrics and Systems Pharmacology, 2016, 5, 20-30.	1.3	30
117	Systematic and quantitative assessment of the effect of chronic kidney disease on CYP2D6 and CYP3A4/5. Clinical Pharmacology and Therapeutics, 2016, 100, 75-87.	2.3	53
118	Examining the Use of a Mechanistic Model to Generate an In Vivo/In Vitro Correlation: Journey Through a Thought Process. AAPS Journal, 2016, 18, 1144-1158.	2.2	15
119	Development of a permeability-limited model of the human brain and cerebrospinal fluid (CSF) to integrate known physiological and biological knowledge: Estimating time varying CSF drug concentrations and their variability using inÂvitro data. Drug Metabolism and Pharmacokinetics, 2016, 31, 224-233.	1.1	54
120	Considering Age Variation When Coining Drugs as High versus Low Hepatic Extraction Ratio. Drug Metabolism and Disposition, 2016, 44, 1099-1102.	1.7	31
121	Metformin and cimetidine: Physiologically based pharmacokinetic modelling to investigate transporter mediated drugâ€“drug interactions. European Journal of Pharmaceutical Sciences, 2016, 88, 70-82.	1.9	92
122	In Vitro-In Vivo Extrapolation Scaling Factors for Intestinal P-glycoprotein and Breast Cancer Resistance Protein: Part II. The Impact of Cross-Laboratory Variations of Intestinal Transporter Relative Expression Factors on Predicted Drug Disposition. Drug Metabolism and Disposition, 2016, 44, 476-480.	1.7	33
123	In Vitro-In Vivo Extrapolation Scaling Factors for Intestinal P-Glycoprotein and Breast Cancer Resistance Protein: Part I: A Cross-Laboratory Comparison of Transporter-Protein Abundances and Relative Expression Factors in Human Intestine and Caco-2 Cells. Drug Metabolism and Disposition, 2016, 44, 297-307.	1.7	50
124	Gut Wall Metabolism. Application of Pre-Clinical Models for the Prediction of Human Drug Absorption and First-Pass Elimination. AAPS Journal, 2016, 18, 589-604.	2.2	46
125	Deconvolution and IVIVC: Exploring the Role of Rate-Limiting Conditions. AAPS Journal, 2016, 18, 321-332.	2.2	30
126	Physiologically Based Pharmacokinetics Is Impacting Drug Development and Regulatory Decision Making. CPT: Pharmacometrics and Systems Pharmacology, 2015, 4, 313-315.	1.3	47

#	Article	IF	Citations
127	Does age affect gastric emptying time? A modelâ€based metaâ€analysis of data from premature neonates through to adults. Biopharmaceutics and Drug Disposition, 2015, 36, 245-257.	1.1	116
128	Complex patients â€•complex DDI: is there a straight way forward?. Biopharmaceutics and Drug Disposition, 2015, 36, 69-70.	1.1	2
129	A proposal for scientific framework enabling specific population drug dosing recommendations. Journal of Clinical Pharmacology, 2015, 55, 1073-1078.	1.0	39
130	Translating Human Effective Jejunal Intestinal Permeability to Surface-Dependent Intrinsic Permeability: a Pragmatic Method for a More Mechanistic Prediction of Regional Oral Drug Absorption. AAPS Journal, 2015, 17, 1177-1192.	2.2	20
131	Ten years of QconCATs: Application of multiplexed quantification to small medically relevant proteomes. International Journal of Mass Spectrometry, 2015, 391, 93-104.	0.7	13
132	Analysis of the impact of controlled release formulations on oral drug absorption, gut wall metabolism and relative bioavailability of CYP3A substrates using a physiologically-based pharmacokinetic model. European Journal of Pharmaceutical Sciences, 2015, 67, 32-44.	1.9	29
133	Prediction of Voriconazole Non-linear Pharmacokinetics Using a Paediatric Physiologically Based Pharmacokinetic Modelling Approach. Clinical Pharmacokinetics, 2015, 54, 567-568.	1.6	6
134	Choice of LC-MS Methods for the Absolute Quantification of Drug-Metabolizing Enzymes and Transporters in Human Tissue: a Comparative Cost Analysis. AAPS Journal, 2015, 17, 438-446.	2.2	36
135	Development and Application of a Mechanistic Pharmacokinetic Model for Simvastatin and its Active Metabolite Simvastatin Acid Using an Integrated Population PBPK Approach. Pharmaceutical Research, 2015, 32, 1864-1883.	1.7	52
136	Application of an LCâ€“MS/MS method for the simultaneous quantification of human intestinal transporter proteins absolute abundance using a QconCAT technique. Journal of Pharmaceutical and Biomedical Analysis, 2015, 110, 27-33.	1.4	53
137	Translational value of liquid chromatography coupled with tandem mass spectrometry-based quantitative proteomics forin vitroâ€“in vivoextrapolation of drug metabolism and transport and considerations in selecting appropriate techniques. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 1357-1369.	1.5	24
138	Drug disposition and modelling before and after gastric bypass: immediate and controlledâ€release metoprolol formulations. British Journal of Clinical Pharmacology, 2015, 80, 1021-1030.	1.1	25
139	Meta-Analysis of Expression of Hepatic Organic Anionâ€“Transporting Polypeptide (OATP) Transporters in Cellular Systems Relative to Human Liver Tissue. Drug Metabolism and Disposition, 2015, 43, 424-432.	1.7	75
140	The Pharmacokinetics of the CYP3A Substrate Midazolam in Morbidly Obese Patients Before and One Year After Bariatric Surgery. Pharmaceutical Research, 2015, 32, 3927-3936.	1.7	58
141	Incorporation of stochastic variability in mechanistic population pharmacokinetic models: handling the physiological constraints using normal transformations. Journal of Pharmacokinetics and Pharmacodynamics, 2015, 42, 349-373.	0.8	13
142	Are Physiologically Based Pharmacokinetic Models Reporting the Right Cmax? Central Venous Versus Peripheral Sampling Site. AAPS Journal, 2015, 17, 1268-1279.	2.2	22
143	Quantitative ADME Proteomics â€“ CYP and UGT Enzymes in the Beagle Dog Liver and Intestine. Pharmaceutical Research, 2015, 32, 74-90.	1.7	47
144	Combining the â€˜bottom upâ€™ and â€˜top downâ€™ approaches in pharmacokinetic modelling: fitting <scp>PBPK</scp> models to observed clinical data. British Journal of Clinical Pharmacology, 2015, 79, 48-55.	1.1	198

#	Article	IF	Citations
145	Meta-Analysis of the Turnover of Intestinal Epithelia in Preclinical Animal Species and Humans. Drug Metabolism and Disposition, 2014, 42, 2016-2022.	1.7	146
146	Lost in Centrifugation: Accounting for Transporter Protein Losses in Quantitative Targeted Absolute Proteomics. Drug Metabolism and Disposition, 2014, 42, 1766-1772.	1.7	35
147	Applications of linking PBPK and PD models to predict the impact of genotypic variability, formulation differences, differences in target binding capacity and target site drug concentrations on drug responses and variability. Frontiers in Pharmacology, 2014, 5, 258.	1.6	46
148	Expansion of a PBPK model to predict disposition in pregnant women of drugs cleared via multiple CYP enzymes, including CYP2B6, CYP2C9 and CYP2C19. British Journal of Clinical Pharmacology, 2014, 77, 554-570.	1.1	91
149	Deciding on Success Criteria for Predictability of Pharmacokinetic Parameters from In Vitro Studies: An Analysis Based on In Vivo Observations. Drug Metabolism and Disposition, 2014, 42, 1478-1484.	1.7	113
150	Precision criteria to derive sample size when designing pediatric pharmacokinetic studies: Which measure of variability should be used?. Journal of Clinical Pharmacology, 2014, 54, 311-317.	1.0	3
151	Protein expression of various hepatic uridine 5â€²â€diphosphate glucuronosyltransferase (UGT) enzymes and their interâ€correlations: a metaâ€analysis. Biopharmaceutics and Drug Disposition, 2014, 35, 353-361.	1.1	44
152	Identification of the Effect of Multiple Polymorphisms on the Pharmacokinetics of Simvastatin and Simvastatin Acid Using a Population-Modeling Approach. Clinical Pharmacology and Therapeutics, 2014, 96, 90-100.	2.3	55
153	PBPK models for the prediction of in vivo performance of oral dosage forms. European Journal of Pharmaceutical Sciences, 2014, 57, 300-321.	1.9	263
154	Quantitative prediction of formulation-specific food effects and their population variability from in vitro data with the physiologically-based ADAM model: A case study using the BCS/BDDCS Class II drug nifedipine. European Journal of Pharmaceutical Sciences, 2014, 57, 240-249.	1.9	39
155	Animal versus human oral drug bioavailability: Do they correlate?. European Journal of Pharmaceutical Sciences, 2014, 57, 280-291.	1.9	157
156	A Mechanistic Framework for In Vitroâ€“In Vivo Extrapolation of Liver Membrane Transporters: Prediction of Drugâ€“Drug Interaction Between Rosuvastatin and Cyclosporine. Clinical Pharmacokinetics, 2014, 53, 73-87.	1.6	136
157	Changes in Individual Drug-Independent System Parameters during Virtual Paediatric Pharmacokinetic Trials: Introducing Time-Varying Physiology into a Paediatric PBPK Model. AAPS Journal, 2014, 16, 568-576.	2.2	72
158	The Use of ROC Analysis for the Qualitative Prediction of Human Oral Bioavailability from Animal Data. Pharmaceutical Research, 2014, 31, 720-730.	1.7	28
159	In vivo methods for drug absorption â€“ Comparative physiologies, model selection, correlations with in vitro methods (IVIVC), and applications for formulation/API/excipient characterization including food effects. European Journal of Pharmaceutical Sciences, 2014, 57, 99-151.	1.9	226
160	Pharmacometrics in Pregnancy: An Unmet Need. Annual Review of Pharmacology and Toxicology, 2014, 54, 53-69.	4.2	76
161	Simultaneous Quantification of the Abundance of Several Cytochrome P450 and Uridine 5â€²-Diphospho-Glucuronosyltransferase Enzymes in Human Liver Microsomes Using Multiplexed Targeted Proteomics. Drug Metabolism and Disposition, 2014, 42, 500-510.	1.7	143
162	Expression of Hepatic Drug-Metabolizing Cytochrome P450 Enzymes and Their Intercorrelations: A Meta-Analysis. Drug Metabolism and Disposition, 2014, 42, 1349-1356.	1.7	179

#	Article	IF	Citations
163	A Re-evaluation and Validation of Ontogeny Functions for Cytochrome P450 1A2 and 3A4 Based on In Vivo Data. Clinical Pharmacokinetics, 2014, 53, 625-636.	1.6	101
164	Oral biopharmaceutics tools â€“ Time for a new initiative â€“ An introduction to the IMI project OrBiTo. European Journal of Pharmaceutical Sciences, 2014, 57, 292-299.	1.9	91
165	Interaction Between Domperidone and Ketoconazole: Toward Prediction of Consequent QTc Prolongation Using Purely In Vitro Information. CPT: Pharmacometrics and Systems Pharmacology, 2014, 3, 1-11.	1.3	23
166	Application of a Physiologically Based Pharmacokinetic Model to Predict OATP1B1â€Related Variability in Pharmacodynamics of Rosuvastatin. CPT: Pharmacometrics and Systems Pharmacology, 2014, 3, 1-9.	1.3	64
167	Can We Rationalize Oral Drug Exposure Following Bariatric Surgery to Meet the Pharmacotherapeutic Needs of a Growing Patient Population? Commentary on: â€œLithium Toxicity Following Roux-en-Y Gastric Bypassâ€. Bariatric Surgical Patient Care, 2014, 9, 81-83.	0.1	0
168	Prediction of the Pharmacokinetics, Pharmacodynamics, and Efficacy of a Monoclonal Antibody, Using a Physiologically Based Pharmacokinetic FcRn Model. Frontiers in Immunology, 2014, 5, 670.	2.2	23
169	The Modulating Effects of Endogenous Substances on Drug Metabolising Enzymes and Implications for Inter-Individual Variability and Quantitative Prediction. Current Drug Metabolism, 2014, 15, 599-619.	0.7	8
170	Application of in vitro-in vivo extrapolation (IVIVE) and physiologically based pharmacokinetic (PBPK) modelling to investigate the impact of the CYP2C8 polymorphism on rosiglitazone exposure. European Journal of Clinical Pharmacology, 2013, 69, 1311-1320.	0.8	20
171	The Simcyp Population Based Simulator: Architecture, Implementation, and Quality Assurance. In Silico Pharmacology, 2013, 1, 9.	1.8	91
172	Alternative Fusion Protein Strategies to Express Recalcitrant QconCAT Proteins for Quantitative Proteomics of Human Drug Metabolizing Enzymes and Transporters. Journal of Proteome Research, 2013, 12, 5934-5942.	1.8	52
173	Absolute abundance and function of intestinal drug transporters: a prerequisite for fully mechanistic in vitroâ€“in vivo extrapolation of oral drug absorption. Biopharmaceutics and Drug Disposition, 2013, 34, 2-28.	1.1	96
174	Do Children Have the Same Vulnerability to Metabolic Drugâ€“Drug Interactions as Adults? A Critical Analysis of the Literature. Journal of Clinical Pharmacology, 2013, 53, 559-566.	1.0	38
175	Predicting drugâ€“drug interactions: application of physiologically based pharmacokinetic models under a systems biology approach. Expert Review of Clinical Pharmacology, 2013, 6, 143-157.	1.3	51
176	A Physiologically Based Pharmacokinetic Modeling Approach to Predict Diseaseâ€“Drug Interactions: Suppression of CYP3A by IL-6. Clinical Pharmacology and Therapeutics, 2013, 94, 260-268.	2.3	82
177	Age Related Changes in Fractional Elimination Pathways for Drugs: Assessing the Impact of Variable Ontogeny on Metabolic Drug-Drug Interactions. Journal of Clinical Pharmacology, 2013, 53, 857-865.	1.0	53
178	Application of permeability-limited physiologically-based pharmacokinetic models: Part Iâ€“digoxin pharmacokinetics incorporating P-glycoprotein-mediated efflux. Journal of Pharmaceutical Sciences, 2013, 102, 3145-3160.	1.6	53
179	Application of permeabilityâ€limited physiologically-based pharmacokinetic models: Part II-prediction of pâ€glycoprotein mediated drugâ€“drug interactions with digoxin. Journal of Pharmaceutical Sciences, 2013, 102, 3161-3173.	1.6	50
180	A Physiologically Based Pharmacokinetic Model to Predict Disposition of CYP2D6 and CYP1A2 Metabolized Drugs in Pregnant Women. Drug Metabolism and Disposition, 2013, 41, 801-813.	1.7	78

#	Article	IF	Citations
181	Evaluation of an In Silico PBPK Postâ€Bariatric Surgery Model through Simulating Oral Drug Bioavailability of Atorvastatin and Cyclosporine. CPT: Pharmacometrics and Systems Pharmacology, 2013, 2, 1-9.	1.3	21
182	Pharmacometrics and Systems Pharmacology Software Tutorials and Use: Comments and Guidelines for PSP Contributions. CPT: Pharmacometrics and Systems Pharmacology, 2013, 2, 86.	1.3	3
183	Response to â€œTheÂLink Between Pharmacodynamics and Physiologically Based Pharmacokinetic Modelsâ€. Clinical Pharmacology and Therapeutics, 2013, 93, 152-152.	2.3	8
184	Accounting for Transporters in Renal Clearance: Towards a Mechanistic Kidney Model (Mech KiM). AAPS Advances in the Pharmaceutical Sciences Series, 2013, , 155-177.	0.2	45
185	Pharmacokinetic-Pharmacodynamic Modeling of Mood and Withdrawal Symptoms in Relation to Plasma Concentrations of Methadone in Patients Undergoing Methadone Maintenance Treatment. Journal of Clinical Psychopharmacology, 2012, 32, 666-671.	0.7	10
186	From Pediatric Covariate Model to Semiphysiological Function for Maturation: Part IIâ€”Sensitivity to Physiological and Physicochemical Properties. CPT: Pharmacometrics and Systems Pharmacology, 2012, 1, 1-8.	1.3	30
187	Sex Differences in the Clearance of CYP3A4 Substrates: Exploring Possible Reasons for the Substrate Dependency and Lack of Consensus. Current Drug Metabolism, 2012, 13, 778-786.	0.7	33
188	Physiologically-based Pharmacokinetic (PBPK) Models for Assessing the Kinetics of Xenobiotics during Pregnancy: Achievements and Shortcomings. Current Drug Metabolism, 2012, 13, 695-720.	0.7	44
189	A PBPK Model to Predict Disposition of CYP3Aâ€Metabolized Drugs in Pregnant Women: Verification and Discerning the Site of CYP3A Induction. CPT: Pharmacometrics and Systems Pharmacology, 2012, 1, 1-10.	1.3	78
190	Trends in oral drug bioavailability following bariatric surgery: examining the variable extent of impact on exposure of different drug classes. British Journal of Clinical Pharmacology, 2012, 74, 774-787.	1.1	45
191	A pregnancy physiologically based pharmacokinetic (pâ€<scp>PBPK</scp>) model for disposition of drugs metabolized by <scp>CYP1A2</scp>, <scp>CYP2D6</scp> and <scp>CYP3A4</scp>. British Journal of Clinical Pharmacology, 2012, 74, 873-885.	1.1	104
192	Physiologically Based Pharmacokinetics Joined With In Vitroâ€“In Vivo Extrapolation of ADME: A Marriage Under the Arch of Systems Pharmacology. Clinical Pharmacology and Therapeutics, 2012, 92, 50-61.	2.3	278
193	Anatomical, Physiological and Metabolic Changes with Gestational Age during Normal Pregnancy. Clinical Pharmacokinetics, 2012, 51, 365-396.	1.6	274
194	Prediction of Concentrationâ€“Time Profile and its Inter-Individual Variability following the Dermal Drug Absorption. Journal of Pharmaceutical Sciences, 2012, 101, 2584-2595.	1.6	52
195	A mechanistic pharmacokinetic model to assess modified oral drug bioavailability post bariatric surgery in morbidly obese patients: interplay between CYP3A gut wall metabolism, permeability and dissolution. Journal of Pharmacy and Pharmacology, 2012, 64, 1008-1024.	1.2	47
196	Physiologically based pharmacokinetic (PBPK) modeling: It is here to stay!. Biopharmaceutics and Drug Disposition, 2012, 33, 47-50.	1.1	29
197	The Proton Pump Inhibitor, Omeprazole, but Not Lansoprazole or Pantoprazole, Is a Metabolism-Dependent Inhibitor of CYP2C19: Implications for Coadministration with Clopidogrel. Drug Metabolism and Disposition, 2011, 39, 2020-2033.	1.7	90
198	Application of a Systems Approach to the Bottom-Up Assessment of Pharmacokinetics in Obese Patients. Clinical Pharmacokinetics, 2011, 50, 809-822.	1.6	70

#	Article	IF	Citations
199	Sources of interindividual variability in IVIVE of clearance: an investigation into the prediction of benzodiazepine clearance using a mechanistic population-based pharmacokinetic model. Xenobiotica, 2011, 41, 623-638.	0.5	50
200	Modeling and predicting drug pharmacokinetics in patients with renal impairment. Expert Review of Clinical Pharmacology, 2011, 4, 261-274.	1.3	138
201	Resurgence in the use of physiologically based pharmacokinetic models in pediatric clinical pharmacology: parallel shift in incorporating the knowledge of biological elements and increased applicability to drug development and clinical practice. Paediatric Anaesthesia, 2011, 21, 291-301.	0.6	143
202	Assessment of algorithms for predicting drugâ€“drug interactions via inhibition mechanisms: comparison of dynamic and static models. British Journal of Clinical Pharmacology, 2011, 71, 72-87.	1.1	65
203	Prediction of time-dependent CYP3A4 drugâ€“drug interactions by physiologically based pharmacokinetic modelling: Impact of inactivation parameters and enzyme turnover. European Journal of Pharmaceutical Sciences, 2011, 43, 160-173.	1.9	95
204	Physiologically-Based Pharmacokinetics. , 2011, , 361-386.		4
205	Fraction absorbed (Fabs): Different connotations and confusion for the literature?. Biopharmaceutics and Drug Disposition, 2011, 32, 301-302.	1.1	2
206	Are there differences in the catalytic activity per unit enzyme of recombinantly expressed and human liver microsomal cytochrome P450 2C9? A systematic investigation into interâ€system extrapolation factors. Biopharmaceutics and Drug Disposition, 2011, 32, 303-318.	1.1	35
207	Bottomâ€up modeling and simulation of tacrolimus clearance: prospective investigation of blood cell distribution, sex and CYP3A5 expression as covariates and assessment of study power. Biopharmaceutics and Drug Disposition, 2011, 32, 498-506.	1.1	7
208	Critique of the Two-Fold Measure of Prediction Success for Ratios: Application for the Assessment of Drug-Drug Interactions. Drug Metabolism and Disposition, 2011, 39, 170-173.	1.7	137
209	Cytochrome P450 Pig Liver Pie: Determination of Individual Cytochrome P450 Isoform Contents in Microsomes from Two Pig Livers Using Liquid Chromatography in Conjunction with Mass Spectrometry. Drug Metabolism and Disposition, 2011, 39, 2130-2134.	1.7	82
210	Methodologies for Investigating Drug Metabolism at the Early Drug Discovery Stage: Prediction of Hepatic Drug Clearance and P450 Contribution. Current Drug Metabolism, 2010, 11, 678-685.	0.7	59
211	Physiologically based mechanistic modelling to predict complex drugâ€“drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gutâ€”The effect of diltiazem on the time-course of exposure to triazolam. European Journal of Pharmaceutical Sciences, 2010, 39, 298-309.	1.9	172
212	Determination of a quantitative relationship between hepatic CYP3A5*1/*3 and CYP3A4 expression for use in the prediction of metabolic clearance in virtual populations. Biopharmaceutics and Drug Disposition, 2010, 31, 516-532.	1.1	32
213	Interplay of Metabolism and Transport in Determining Oral Drug Absorption and Gut Wall Metabolism: A Simulation Assessment Using the “Advanced Dissolution, Absorption, Metabolism (ADAM)” Model. Current Drug Metabolism, 2010, 11, 716-729.	0.7	160
214	A Semi-Mechanistic Model to Predict the Effects of Liver Cirrhosis on Drug Clearance. Clinical Pharmacokinetics, 2010, 49, 189-206.	1.6	178
215	Influence of Î²2-adrenoceptor gene polymorphisms on Î²2-adrenoceptor expression in human lung. Pulmonary Pharmacology and Therapeutics, 2010, 23, 71-77.	1.1	1
216	Translation of In Vitro Metabolic Data to Predict In Vivo Drugâ€“Drug Interactions: IVIVE and Modeling and Simulations. , 2010, , 317-341.		4

#	Article	IF	Citations
217	Singleâ€Dose Pharmacokinetic Study of Clomiphene Citrate Isomers in Anovular Patients With Polycystic Ovary Disease. Journal of Clinical Pharmacology, 2009, 49, 147-154.	1.0	28
218	A Framework for Assessing Inter-individual Variability in Pharmacokinetics Using Virtual Human Populations and Integrating General Knowledge of Physical Chemistry, Biology, Anatomy, Physiology and Genetics: A Tale of â€˜Bottom-Upâ€™ vs â€˜Top-Downâ€™ Recognition of Covariates. Drug Metabolism and Pharmacokinetics, 2009, 24, 53-75.	1.1	311
219	Utilization of estimated physicochemical properties as an integrated part of predicting hepatic clearance in the early drug-discovery stage: Impact of plasma and microsomal binding. Xenobiotica, 2009, 39, 227-235.	0.5	36
220	Modified-Release Hydrocortisone to Provide Circadian Cortisol Profiles. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 1548-1554.	1.8	265
221	Metabolism of Dextrorphan by CYP2D6 in Different Recombinantly Expressed Systems and its Implications for the In Vitro Assessment of Dextromethorphan Metabolism. Journal of Pharmaceutical Sciences, 2009, 98, 763-771.	1.6	13
222	Assessment of inter-individual variability in predicted phenytoin clearance. European Journal of Clinical Pharmacology, 2009, 65, 1203-1210.	0.8	16
223	Assessing the efficiency of mixed effects modelling in quantifying metabolism based drugâ€“drug interactions: using in vitro data as an aid to assess study power. Pharmaceutical Statistics, 2009, 8, 186-202.	0.7	12
224	Contribution of the activities of CYP3A, CYP2D6, CYP1A2 and other potential covariates to the disposition of methadone in patients undergoing methadone maintenance treatment. British Journal of Clinical Pharmacology, 2009, 67, 29-37.	1.1	55
225	Population-Based Mechanistic Prediction of Oral Drug Absorption. AAPS Journal, 2009, 11, 225-237.	2.2	365
226	The Simcyp^{Â®}Population-based ADME Simulator. Expert Opinion on Drug Metabolism and Toxicology, 2009, 5, 211-223.	1.5	438
227	Evaluation of the relationship between plasma concentrations of en- and zuclomiphene and induction of ovulation in anovulatory women being treated with clomiphene citrate. Fertility and Sterility, 2009, 91, 1135-1140.	0.5	11
228	Towards a Quantitative Framework for the Prediction of DDIs Arising from Cytochrome P450 Induction. Current Drug Metabolism, 2009, 10, 420-432.	0.7	74
229	Development of CYP2D6 and CYP3A4 in the First Year of Life. Clinical Pharmacology and Therapeutics, 2008, 83, 670-671.	2.3	68
230	Modifiedâ€release hydrocortisone for circadian therapy: a proofâ€ofâ€principle study in dexamethasoneâ€suppressed normal volunteers. Clinical Endocrinology, 2008, 68, 130-135.	1.2	79
231	Covariation of Human Microsomal Protein Per Gram of Liver with Age: Absence of Influence of Operator and Sample Storage May Justify Interlaboratory Data Pooling. Drug Metabolism and Disposition, 2008, 36, 2405-2409.	1.7	104
232	CYP2D6 is Primarily Responsible for the Metabolism of Clomiphene. Drug Metabolism and Pharmacokinetics, 2008, 23, 101-105.	1.1	19
233	Cytochrome P450 Turnover: Regulation of Synthesis and Degradation, Methods for Determining Rates, and Implications for the Prediction of Drug Interactions. Current Drug Metabolism, 2008, 9, 384-393.	0.7	220
234	The Consequences of 3,4-Methylenedioxymethamphetamine Induced CYP2D6 Inhibition in Humans. Journal of Clinical Psychopharmacology, 2008, 28, 523-529.	0.7	49

#	Article	IF	Citations
235	Modelling and simulation in prediction of human xenobiotic absorption, distribution, metabolism and excretion (ADME): in vitroâ€“in vivo extrapolations (IVIVE). Xenobiotica, 2007, 37, 1013-1014.	0.5	19
236	Scaling Factors for the Extrapolation of In Vivo Metabolic Drug Clearance From In Vitro Data: Reaching a Consensus on Values of Human Micro-somal Protein and Hepatocellularity Per Gram of Liver. Current Drug Metabolism, 2007, 8, 33-45.	0.7	398
237	Prediction of Intestinal First-Pass Drug Metabolism. Current Drug Metabolism, 2007, 8, 676-684.	0.7	329
238	Disparity in Holoprotein/Apoprotein Ratios of Different Standards Used for Immunoquantification of Hepatic Cytochrome P450 Enzymes. Drug Metabolism and Disposition, 2007, 35, 1733-1736.	1.7	15
239	Misuse of the Well-Stirred Model of Hepatic Drug Clearance: Fig. 1.. Drug Metabolism and Disposition, 2007, 35, 501-502.	1.7	153
240	Evaluation of an existing nomogram for predicting the response to clomiphene citrate. Fertility and Sterility, 2007, 87, 597-602.	0.5	21
241	Incorporating In Vitro Information on Drug Metabolism Into Clinical Trial Simulations to Assess the Effect of CYP2D6 Polymorphism on Pharmacokinetics and Pharmacodynamics: Dextromethorphan as a Model Application. Journal of Clinical Pharmacology, 2007, 47, 175-186.	1.0	39
242	Mechanism-based inactivation of human cytochrome P450 enzymes: strategies for diagnosis and drugâ€“drug interaction risk assessment. Xenobiotica, 2007, 37, 1225-1256.	0.5	70
243	Determination by liquid chromatographyâ€“mass spectrometry of clomiphene isomers in the plasma of patients undergoing treatment for the induction of ovulation. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2007, 847, 296-299.	1.2	21
244	Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nature Reviews Drug Discovery, 2007, 6, 140-148.	21.5	471
245	Influence of Î²₂â€adrenoceptor gene polymorphisms on Î²₂â€adrenoceptorâ€mediated responses in human lung mast cells. British Journal of Pharmacology, 2007, 152, 323-331.	2.7	18
246	Response from authors. Journal of Clinical Pharmacy and Therapeutics, 2007, 32, 325-326.	0.7	0
247	The use of mechanistic DM-PK-PD modelling to assess the power of pharmacogenetic studies ? CYP2C9 and warfarin as an example. British Journal of Clinical Pharmacology, 2007, 64, 14-26.	1.1	41
248	Kinetics of the time-dependent inactivation of CYP2D6 in cryopreserved human hepatocytes by methylenedioxymethamphetamine (MDMA). European Journal of Pharmaceutical Sciences, 2007, 31, 53-61.	1.9	19
249	Theoretical assessment of a new experimental protocol for determining kinetic values describing mechanism (time)-based enzyme inhibition. European Journal of Pharmaceutical Sciences, 2007, 31, 232-241.	1.9	28
250	Inactivation of CYP2D6 by methylenedioxymethamphetamine in different recombinant expression systems. European Journal of Pharmaceutical Sciences, 2007, 32, 8-16.	1.9	12
251	Prediction ofin vivodrug clearance fromin vitrodata. II: Potential inter-ethnic differences. Xenobiotica, 2006, 36, 499-513.	0.5	83
252	Prediction of the Clearance of Eleven Drugs and Associated Variability in Neonates, Infants and Children. Clinical Pharmacokinetics, 2006, 45, 931-956.	1.6	437

#	Article	IF	Citations
253	Prediction ofin vivodrug clearance fromin vitrodata. I: Impact of inter-individual variability. Xenobiotica, 2006, 36, 473-497.	0.5	209
254	Prediction of metabolic drug clearance in humans:In vitroâ€“in vivoextrapolationvsallometric scaling. Xenobiotica, 2006, 36, 567-580.	0.5	88
255	Implications of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of MDMA. Journal of Psychopharmacology, 2006, 20, 842-849.	2.0	77
256	Circadian hydrocortisone infusions in patients with adrenal insufficiency and congenital adrenal hyperplasia. Clinical Endocrinology, 2006, 65, 45-50.	1.2	83
257	A six-year evaluation of methadone prescribing practices at a substance misuse treatment centre in the UK. Journal of Clinical Pharmacy and Therapeutics, 2006, 31, 477-484.	0.7	12
258	Does previous response to clomifene citrate influence the selection of gonadotropin dosage given in subsequent superovulation treatment cycles?. Journal of Assisted Reproduction and Genetics, 2006, 23, 427-431.	1.2	0
259	Prediction of Plasma Protein Binding Displacement and its Implications for Quantitative Assessment of Metabolic Drugâ€“Drug Interactions from In Vitro Data. Journal of Pharmaceutical Sciences, 2006, 95, 2778-2787.	1.6	33
260	A Critical Evaluation of the Experimental Design of Studies of Mechanism Based Enzyme Inhibition, with Implications for In Vitro-In Vivo Extrapolation. Current Drug Metabolism, 2006, 7, 315-334.	0.7	130
261	The impact of experimental design on assessing mechanism-based inactivation of CYP2D6 by MDMA (Ecstasy). Journal of Psychopharmacology, 2006, 20, 834-841.	2.0	25
262	Can Saliva Replace Plasma for the Monitoring of Methadone?. Therapeutic Drug Monitoring, 2005, 27, 580-586.	1.0	23
263	Kinetic values for mechanism-based enzyme inhibition: Assessing the bias introduced by the conventional experimental protocol. European Journal of Pharmaceutical Sciences, 2005, 26, 334-340.	1.9	58
264	Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells. International Journal of Cancer, 2005, 113, 364-371.	2.3	152
265	Changes in liver volume from birth to adulthood: A meta-analysis. Liver Transplantation, 2005, 11, 1481-1493.	1.3	280
266	Changes to methadone clearance during pregnancy. European Journal of Clinical Pharmacology, 2005, 61, 763-768.	0.8	82
267	3.9. Toxicokinetics and Metabolism. ATLA Alternatives To Laboratory Animals, 2005, 33, 147-175.	0.7	16
268	Preliminary evidence of the cardiovascular effects of polysubstance misuse in nightclubs. Journal of Psychopharmacology, 2005, 19, 67-70.	2.0	17
269	Timing and Type of Glucocorticoid Replacement in Adult Congenital Adrenal Hyperplasia. Hormone Research in Paediatrics, 2005, 64, 67-70.	0.8	15
270	MECHANISM-BASED INACTIVATION OF CYP2D6 BY METHYLENEDIOXYMETHAMPHETAMINE. Drug Metabolism and Disposition, 2004, 32, 1213-1217.	1.7	90

#	Article	IF	Citations
271	PREDICTING THE CLEARANCE OF CYP2C9 SUBSTRATES. Drug Metabolism and Disposition, 2004, 32, 1522-1522.	1.7	9
272	Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors. Xenobiotica, 2004, 34, 151-178.	0.5	201
273	Weight-related dosing, timing and monitoring hydrocortisone replacement therapy in patients with adrenal insufficiency. Clinical Endocrinology, 2004, 61, 367-375.	1.2	210
274	Cytochrome P450 3A expression and activity in the human small intestine. Clinical Pharmacology and Therapeutics, 2004, 76, 391-391.	2.3	77
275	â€˜In silicoâ€™ simulations to assess the â€˜in vivoâ€™ consequences of â€˜in vitroâ€™ metabolic drugâ€“drug interactions. Drug Discovery Today: Technologies, 2004, 1, 441-448.	4.0	197
276	Monitoring plasma concentrations to individualize treatment with clomiphene citrate. Fertility and Sterility, 2004, 81, 1187-1193.	0.5	50
277	Influence of Dose, Cigarette Smoking, Age, Sex, and Metabolic Activity on Plasma Clozapine Concentrations. Journal of Clinical Psychopharmacology, 2004, 24, 70-78.	0.7	229
278	Assessment of In Vivo CYP2D6 Activity: Differential Sensitivity of Commonly Used Probes to Urine pH. Journal of Clinical Pharmacology, 2004, 44, 1398-1404.	1.0	25
279	Comparison of the rates of disintegration, gastric emptying, and drug absorption following administration of a new and a conventional paracetamol formulation, using gamma scintigraphy. Pharmaceutical Research, 2003, 20, 1668-1673.	1.7	86
280	The effects of dose staggering on metabolic drugâ€“drug interactions. European Journal of Pharmaceutical Sciences, 2003, 20, 223-232.	1.9	40
281	A discordance between cytochrome P450 2D6 genotype and phenotype in patients undergoing methadone maintenance treatment. British Journal of Clinical Pharmacology, 2003, 56, 220-224.	1.1	39
282	Physiologically based modelling of inhibition of metabolism and assessment of the relative potency of drug and metabolite: dextromethorphan vs . dextrorphan using quinidine inhibition. British Journal of Clinical Pharmacology, 2003, 56, 57-67.	1.1	38
283	Inter-individual variability in levels of human microsomal protein and hepatocellularity per gram of liver. British Journal of Clinical Pharmacology, 2003, 56, 433-440.	1.1	154
284	Determination of midazolam and 1â€²-hydroxymidazolam by liquid chromatographyâ€“mass spectrometry in plasma of patients undergoing methadone maintenance treatment. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2003, 783, 303-307.	1.2	27
285	Influence of the thr164ile polymorphism in the Î²2-adrenoceptor on the effects of Î²-adrenoceptor agonists on human lung mast cells. International Immunopharmacology, 2003, 3, 91-95.	1.7	17
286	A New Rapidly Absorbed Paracetamol Tablet Containing Sodium Bicarbonate. II. Dissolution Studies and In Vitro/In Vivo Correlation. Drug Development and Industrial Pharmacy, 2002, 28, 533-543.	0.9	33
287	Contribution of midazolam and its 1-hydroxy metabolite to preoperative sedation in children: a pharmacokinetic-pharmacodynamic analysis. British Journal of Anaesthesia, 2002, 89, 428-437.	1.5	55
288	Analysis of Solvent Central Nervous System Toxicity and Ethanol Interactions Using a Human Population Physiologically Based Kinetic and Dynamic Model. Regulatory Toxicology and Pharmacology, 2002, 35, 165-176.	1.3	19

#	Article	IF	Citations
289	A New Rapidly Absorbed Paracetamol Tablet Containing Sodium Bicarbonate. I. A Four-Way Crossover Study to Compare the Concentrationâ€“Time Profile of Paracetamol from the New Paracetamol/Sodium Bicarbonate Tablet and a Conventional Paracetamol Tablet in Fed and Fasted Volunteers. Drug Development and Industrial Pharmacy, 2002, 28, 523-531.	0.9	44
290	The effects of portal shunts on intestinal cytochrome P450 3A activity. Hepatology, 2002, 35, 1549-1550.	3.6	34
291	An indirect response model of homocysteine suppression by betaine: optimising the dosage regimen of betaine in homocystinuria. British Journal of Clinical Pharmacology, 2002, 54, 140-146.	1.1	28
292	Contribution of midazolam and its 1-hydroxy metabolite to preoperative sedation in children: a pharmacokinetic-pharmacodynamic analysis. British Journal of Anaesthesia, 2002, 89, 428-37.	1.5	18
293	The Placebo Response to Citric Acid-induced Cough: Pharmacodynamics and Gender Differences. Pulmonary Pharmacology and Therapeutics, 2001, 14, 315-319.	1.1	30
294	Contribution of dihydrocodeine and dihydromorphine to analgesia following dihydrocodeine administration in man: a PK-PD modelling analysis. British Journal of Clinical Pharmacology, 2001, 52, 35-43.	1.1	36
295	The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. British Journal of Cancer, 2001, 84, 1126-1134.	2.9	295
296	Journal impact factors: a â€˜bioequivalenceâ€™ issue?. British Journal of Clinical Pharmacology, 2001, 51, 111-117.	1.1	19
297	Population-based pharmacokinetic approach for methadone monitoring of opiate addicts: potential clinical utility. Addiction, 2000, 95, 1771-1783.	1.7	50
298	Parkinson's disease and CYP1A2 activity. British Journal of Clinical Pharmacology, 2000, 50, 303-309.	1.1	16
299	The 1'-hydroxylation of Rac-bufuralol by rat brain microsomes. Drug Metabolism and Disposition, 2000, 28, 1094-9.	1.7	7
300	The antitussive effect of dextromethorphan in relation to CYP2D6 activity. British Journal of Clinical Pharmacology, 1999, 48, 382-387.	1.1	45
301	Population pharmacokinetics of methadone in opiate users: characterization of timeâ€dependent changes. British Journal of Clinical Pharmacology, 1999, 48, 43-52.	1.1	97
302	In-vivo indices of enzyme activity. Pharmacogenetics and Genomics, 1999, 9, 277-286.	5.7	44
303	Determination of drug-metabolizing enzyme activity in vivo : pharmacokinetic and statistical issues. Xenobiotica, 1998, 28, 1255-1273.	0.5	36
304	Meta-analysis of studies of the CYP2D6 polymorphism in relation to lung cancer and Parkinson??s disease. Pharmacogenetics and Genomics, 1998, 8, 227-238.	5.7	100
305	Population-based modeling to demonstrate extrapancreatic effects of tolbutamide. American Journal of Physiology - Endocrinology and Metabolism, 1998, 274, E758-E771.	1.8	6
306	The Use of Tolbutamide-Induced Hypoglycemia to Examine the Intraislet Role of Insulin in Mediating Glucagon Release in Normal Humans*. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 1458-1461.	1.8	40

#	Article	IF	Citations
307	Is Cmax/AUC Useful for Bioequivalence Testing?. Journal of Pharmaceutical Sciences, 1997, 86, 1504-1505.	1.6	7
308	The pharmacokinetics of methadone in healthy subjects and opiate users. British Journal of Clinical Pharmacology, 1997, 44, 325-334.	1.1	91
309	The Use of Tolbutamide-Induced Hypoglycemia to Examine the Intraislet Role of Insulin in Mediating Glucagon Release in Normal Humans. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 1458-1461.	1.8	34
310	Caffeine urinary metabolite ratios as markers of enzyme activity: a theoretical assessment. Pharmacogenetics and Genomics, 1996, 6, 121-149.	5.7	118
311	Similar Physiological and Symptomatic Responses to Sulphonylurea and Insulin Induced Hypoglycaemia in Normal Subjects. Diabetic Medicine, 1996, 13, 634-641.	1.2	15
312	The accumulation of mercaptopurine metabolites in age fractionated red blood cells.. British Journal of Clinical Pharmacology, 1995, 40, 217-222.	1.1	22
313	Sensitivity of Indirect Metrics for Assessing â€œRateâ€•in Bioequivalence Studiesâ€”Moving the â€œGoalpostsâ€• or Changing the â€œGameâ€• Journal of Pharmaceutical Sciences, 1994, 83, 1554-1557.	1.6	43
314	Debrisoquine and metoprolol oxidation in Zambians: a population study. Pharmacogenetics and Genomics, 1993, 3, 205-208.	5.7	29
315	Precision medicine technology reality not hype -ÂThe example ofÂmodel-informed precisionÂdosing. F1000Research, 0, 8, 1709.	0.8	1
316	Examining Physiologically-Based Pharmacokinetic (PBPK) Model Assumptions for Cross-Tissue Similarity of K_{cat}: The Case Example of Uridine 5'-diphosphate Glucuronosyltransferase (UGT). Drug Metabolism and Disposition, 0, , DMD-COM-2021-000813.	1.7	3